| Serial Number | 99457431 |
| Word Mark | OATH |
| Filing Date | Wednesday, October 22, 2025 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Thursday, January 22, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceutical preparations for alleviating side effects of cancer treatments; Pharmaceutical preparations for alleviating side effects of chemotherapy; Pharmaceutical preparations for alleviating side effects of radiation therapy; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments; Pharmaceutical preparations for alleviating side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for alleviating side effects of immunotherapy treatments; Pharmaceutical preparations for alleviating gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for stimulating appetite; Pharmaceutical preparations for preventing weight loss; Pharmaceutical preparations for protecting bone marrow and the production of bone marrow; Pharmaceutical preparations for protecting stem cells and stimulating the production of stem cells; Pharmaceutical preparations for increasing resiliency of stem cells, increasing the number of stem cells, and preventing the reduction of stem cell populations; Pharmaceutical preparations for protecting blood cells, alleviating anemia, neutropenia, thrombocytopenia, and alleviating low blood counts; Pharmaceutical preparations for alleviating dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of side effects of cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of chemotherapy; Pharmaceutical preparations for the prevention and treatment of side effects of radiation therapy; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments; Pharmaceutical preparations for the prevention and treatment of side effects of targeted cancer treatments, namely, tyrosine kinase inhibitors; Pharmaceutical preparations for the prevention and treatment of side effects of immunotherapy treatments; Pharmaceutical preparations for the prevention and treatment of gastrointestinal distress, mucocitis, nausea, vomiting and diarrhea; Pharmaceutical preparations for the prevention and treatment of loss of appetite; Pharmaceutical preparations for the prevention and treatment of weight loss; Pharmaceutical preparations for the treatment and prevention of bone marrow damage; Pharmaceutical preparations for the treatment and prevention of stem cell damage and reduction of stem cell populations; Pharmaceutical preparations for the treatment and prevention of blood cell damage, anemia, and low blood count; Pharmaceutical preparations for the treatment and prevention of dose limiting side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments; Pharmaceutical preparations for the treatment and prevention of side effects of cancer treatments, chemotherapy, radiation therapy, targeted cancer treatments and immunotherapy treatments, namely, reduced fertility; Pharmaceutical preparations for supporting stem cell health and production; Pharmaceutical preparations for supporting stem cell health and production, namely for stimulating uterine, bone marrow and gastrointestinal track stem cell production; Pharmaceutical preparations for the treatment of radiation exposure; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of inflammatory bowel disease, ulcerative colitis and other inflammatory bowel disorders; Pharmaceutical preparations for the enhancement of chemotherapy; Pharmaceutical preparations for the enhancement of immunotherapy; Fertility enhancement preparations |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, October 22, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Caper Labs, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Francisco, CA 94129 US |
| Event Date | Event Description |
| Wednesday, October 22, 2025 | NEW APPLICATION ENTERED |
| Wednesday, October 22, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, October 22, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 12, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, December 12, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, December 12, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, January 21, 2026 | ASSIGNED TO EXAMINER |
| Thursday, January 22, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, January 22, 2026 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Thursday, January 22, 2026 | NON-FINAL ACTION WRITTEN |
| Thursday, January 22, 2026 | NON-FINAL ACTION E-MAILED |
| Thursday, January 22, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, April 22, 2026 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, April 22, 2026 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |